6 days ago • Posted by Djellza Kolloni

CureVac has struggled to keep up with rivals in the pandemic

Several events justifies CureVac troubles to keep up with rivals. First, a brain haemorrhage forced the founder to step aside in march. Then, delays put the company months behind its rivals. Finally, its trials results revealed an overall efficacy of 48%, below the cut-off required. Source: Financial Times

bg_nwsletter